Sangamo to put ‘substantially all’ assets for sale in bankruptcy, lines up Lilly and Astellas as buyers
Gene therapy pioneer Sangamo Therapeutics files for bankruptcy, with Lilly and Astellas racing to acquire its assets
📍 Aftermath
Sangamo Therapeutics filed for Chapter 11 bankruptcy and announced plans to sell substantially all its assets. Eli Lilly and Astellas emerged as the leading bidders, with preliminary agreements allocating portions of the company’s portfolio to each.
The bankruptcy process proceeded with the asset sales as the central focus.
Epilogue added 44d ago, after coverage quieted.
How fast it spread
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Sangamo Therapeutics has filed for Chapter 11 bankruptcy protection and plans to sell ‘substantially all’ of its assets. Coverage emphasizes the strategic value of Sangamo’s gene-editing technology, particularly its zinc-finger nuclease platform, which could bolster Lilly’s and Astellas’ pipelines.
Reports from *citybiz*, *Law360*, and *Fierce Biotech* note the move follows years of financial struggles and failed clinical trials, though Sangamo’s intellectual property remains a key draw. Next steps include formal auction processes and regulatory approvals for asset transfers.
Lilly and Astellas are expected to compete for Sangamo’s most advanced programs, with potential implications for the broader biotech and pharmaceutical sectors.
Synthesized by headlinez.news from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (83% supported) Updated 46d ago.
Sources (8)
- Sangamo Therapeutics, Inc. Filed for Bankruptcy marketscreener.com · 46d ago
- Lilly, Astellas bid on Sangamo's assets after bankruptcy filing FirstWord Pharma · 46d ago
- Sangamo Therapeutics files for bankruptcy as Lilly and Astellas split assets The Business Journals · 46d ago
- Sangamo Therapeutics Files for Chapter 11 Bankruptcy Protection citybiz · 46d ago
- Gene Therapy Developer Sangamo Hits Ch. 11 With Sale Plans Law360 · 46d ago
- Sangamo Therapeutics Sets Stalking Horse Sales: $50M to Eli Lilly, Up to $50M to Astellas TradingView · 46d ago
- UPDATE: Lilly, Astellas circle Sangamo assets as biotech files for bankruptcy BioSpace · 46d ago
- Sangamo to put ‘substantially all’ assets for sale in bankruptcy, lines up Lilly and Astellas as buyers Fierce Biotech · 46d ago
Quick answers
Why is Sangamo selling its assets?
Sangamo filed for Chapter 11 bankruptcy and plans to sell ‘substantially all’ of its assets to address financial distress, as stated in coverage from *citybiz* and *Law360*.
Which companies are bidding for Sangamo’s assets?
Eli Lilly and Astellas Pharma are the two primary buyers identified in reports, with preliminary bids of up to $50 million each for specific assets, per *TradingView* and *BioSpace*.
What technology is Sangamo selling?
Coverage highlights Sangamo’s zinc-finger nuclease gene-editing platform as a key asset, which could enhance the pipelines of potential buyers like Lilly and Astellas.
Topics
Related trends
MapLight shares sink on mixed ph. 2 schizophrenia readout
MapLight Therapeutics stock plummeted 73% following mixed phase 2 trial data for its schizophrenia candidate, ML-007C-MA.
FDA staff flags data concerns about Capricor's therapy; shares plunge
Capricor Therapeutics faces market volatility and legal investigations following the release of FDA staff documents regarding its therapy, Deramiocel.
Argenx to Buy Forte Biosciences for $2.2 Billion
A $2.2 billion acquisition agreement marks a significant shift in the immunology market, as Argenx moves to absorb Forte Biosciences.
This Billionaire Made $360 Million Selling His Psychedelic Company To Eli Lilly
Eli Lilly's $3.8 billion acquisition of a psychedelic company draws industry attention to the firm’s renewed focus on neuropsychiatry and Alzheimer's prevention.
Precise DNA base editing using AlphaFold3-based contact modelling
Researchers are utilizing AlphaFold3-based contact modelling to redesign gene-editing proteins, aiming to improve safety in CRISPR applications.
Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout
Sanofi has officially discontinued development of its eczema drug amlitelimab, marking a significant shift in its pipeline strategy.